DNDN: Nice. Could be a retrace to 11 short term but there's also that big gap below that makes it attractive for Puts now.
The only thing that usually scares me about these bio-pharma stocks is that they often have some patents and buyouts coming from out of nowhere which makes the chart T/A obsolete.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.